nChroma Bio
PrivateLast Round
Series I
Dec 11, 2024
Total Funding Raised
$435M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
nChroma Bio is a biotechnology company that develops in vivo targeted genetic medicines to treat a wide array of diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
nChroma Bio Comparables
Compare nChroma Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 90% | |
| Epigenic Therapeutics | 86% | |
| Epicrispr Biotechnologies | 85% |
For institutional investors. Book with your work email.
nChroma Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series I | Dec 11, 2024 | ||||
| Series B | Mar 1, 2023 | ||||
| Series A | Nov 17, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
nChroma Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Seed, Series B, Series A, Series I |
| Janus Henderson Group | Series I, Series B, Series A |
| Omega Funds | Series I, Series B, Series A |
| GV | Series I, Seed, Series B |
| DCVC Bio | Series I, Series B |
| F-Prime Capital | Series I, Seed |
| Sixth Street Partners | Series I |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 86% MoM.
- Jun 21, 2026
Monthly visitors increased 65% MoM.
For institutional investors. Book with your work email.
nChroma Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about nChroma Bio's valuation, stock price, and market status.
Is nChroma Bio a public or private company?
nChroma Bio is a private company.
What is the current stock price of nChroma Bio?
nChroma Bio is a private company, so its shares have no public market price. Caplight tracks nChroma Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is nChroma Bio worth (valuation)?
Valuation information for nChroma Bio is not publicly available.
Can I buy nChroma Bio stock?
nChroma Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was nChroma Bio's last funding round?
nChroma Bio's most recent funding round was Series I on December 11, 2024.
Who are the main investors in nChroma Bio?
Key investors in nChroma Bio include Newpath Partners, GV, F-Prime Capital, ARCH Venture Partners, Accomplice.
Will nChroma Bio IPO soon?
No public IPO plans have been announced for nChroma Bio.
How can I track nChroma Bio secondary market activity?
Caplight tracks bids, offers, and trades in nChroma Bio's shares on secondary markets.